Cisplatin and Vinorelbine Chemotherapy in Recurrent Vulvar Carcinoma

Abstract

Purpose: To evaluate the activity and toxicity of the combination of cisplatin and vinorelbine in patients with recurrent carcinoma of the vulva that has not been previously treated with chemotherapy. Patients and Methods: Sixteen women with a median age of 65 years (range 43–79) with recurrent vulvar carcinoma were enrolled in the study. Nine patients had local recurrent disease (perineum, vagina and/or vulva), whereas 7 had disease in the groin; 9 patients had received prior radiotherapy. Cisplatin was administered intravenously on day 1 and vinorelbine was given on day 1 immediately after cisplatin and on day 8. Results: A total of 68 cycles of chemotherapy were administered. Fifteen women were assessed for response. Objective responses were recorded in 6 patients (40%) – with 4 patients (27%) achieving a complete response and 2 (13%) achieving a partial response –, whereas 4 patients (27%) had stable disease and 5 had progressive disease. The median progression-free survival was 10 months (range 3–17), whereas the overall survival from the beginning of the chemotherapy was 19 months (range 1–30). Due to the small number of patients, no significant correlation with site of recurrence could be found. Conclusion: The combination of cisplatin and vinorelbine is a well-tolerated and active regimen in the treatment of patients with recurrent vulvar carcinoma.

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva

“…Responses and stabilization of disease was not very durable with patients on average showing progression by 3 months. These results are comparable to those reported for standard chemotherapies utilized in patients such as these (Table 5) [29][30][31][32][33][34]. Though not formally evaluated with quality of life assessments patients did report improvement in tumor related symptoms, as documented in office notes, during these periods of benefit.…”

Management of patients with vulvar cancer: a perspective review according to tumour stage

“…Combination therapy with cisplatin and vinorelbine lead to a progression-free survival of 10 months and overall survival of 19 months in a group of patients with recurrent disease after radiotherapy [Cormio et al 2009]. In a further study enrolling patients with locally advanced vulvar cancer the efficacy of a combination therapy with bleomycin, methotrexate and lomustine was analyzed (median overall survival 7.8 months) although significant side effects were noted [Wagenaar et al 2001].…”

Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature

“…Data are limited due to the rarity of the disease. Table 1 highlights the chemotherapy regimen to treat recurrent/metastatic vulvar carcinoma [9][10][11][12][13][14][15][16].…”